Pradaxa 150mg available for stroke risk reduction

Pradaxa (dabigatran etexilate capsules) 150mg, an oral direct thrombin inhibitor, will be made available by Boehringer Ingelheim on November 3, 2010. Pradaxa is approved by the FDA to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib). The 75mg dosage strength of Pradaxa will be made available in the coming weeks.

For more information call (800) 542-6257 or visit www.pradaxa.com.